Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04661852 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib With Topotecan-Cyclophosphamide
A Phase 1 study of Refractory Osteosarcoma and Relapsed Osteosarcoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT04661852 is a Phase 1 study of Refractory Osteosarcoma and Relapsed Osteosarcoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants, below the 36-participant average among 7 other Refractory Osteosarcoma trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04661852, a Phase 1 study of Refractory Osteosarcoma and Relapsed Osteosarcoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. * The names of the drugs are: * Cabozantinib * Topotecan * Cyclophosphamide * The names of the non-investigational supportive care drugs are: * Filgrastim, pegfilgrastim, or a related growth factor.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Cabozantinib
- DRUG Topotecan
- DRUG Myeloid growth factor
Study Locations (2)
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-12-23 |
| Est. Completion | 2022-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04661852
The ClinicalTrials.gov registry entry for NCT04661852 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 7 other Refractory Osteosarcoma trials with a reported enrollment target (67% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Osteosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04661852 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04661852 about?
NCT04661852 is a clinical study titled "Cabozantinib With Topotecan-Cyclophosphamide". This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. * The names of the drugs are: * Cabozantinib * Topotecan * Cyclophosphamide * The names of the non-investigational supportive care drugs ar...
What is the current status of trial NCT04661852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-12-23. Estimated completion is 2022-10-24.
What conditions does trial NCT04661852 study?
This clinical trial studies the following conditions: Refractory Osteosarcoma, Relapsed Osteosarcoma, Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma.
What interventions are being tested in trial NCT04661852?
The interventions under investigation include: Cyclophosphamide (DRUG), Cabozantinib (DRUG), Topotecan (DRUG), Myeloid growth factor (DRUG).
Who is sponsoring clinical trial NCT04661852?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04661852 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
RECRUITING · Phase 1
-
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
RECRUITING · Phase 1
-
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
RECRUITING · Phase 1
-
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
ACTIVE NOT RECRUITING · Phase 1
-
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
COMPLETED · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.